New innovation marketplace aims to disrupt traditional healthcare decision-making

Lucro is a new marketplace that aims to accelerate decision-making for healthcare leaders, helping them discover, compare and collaborate with peers around innovative solutions.

That's the goal for the endeavor, backed by Martin Ventures, an investment company focused on healthcare and technology.

Expected to launch next spring, Lucro already has many of the largest healthcare organizations in the U.S., collectively representing more than 1,000 hospitals, on board as early adopters, according to a release.

“Until now, information on innovative, disruptive solutions for healthcare has been hard to find and even harder to trust,” said Bruce Brandes, CEO and founder of Lucro. “Healthcare can no longer afford to lag behind other industries in enterprise strategy and solutions decision-making. With Lucro, healthcare leaders can engage a community of colleagues and peers to accelerate decisions with greater clarity and lower risk.”

Lucro’s capabilities include:

  • A comprehensive catalog of established and emerging companies and their products for healthcare;
  • The ability to organize individual products within project boards, enabling the pinning of individual products to be grouped into a comprehensive solution;
  • Insights from trusted colleagues through ratings, reviews and polling;
  • Private group collaboration to raise consistent best practices enterprise-wide; and
  • Aggregation of specific, valuable third party insights into a fuller context to inform more comprehensive decision-making.

Through the Lucro marketplace, "emerging and established solution providers gain increased market visibility, access and unprecedented insights to find the right potential customers and catalyze the growth of the industry’s most promising and proven solutions," according to the release.

Some information has been pre-populated into Lucro for most companies targeting healthcare organizations, but they also invite solutions providers to engage now to complete their “solutions card” or company profile about their products. There is no cost to buyers, sellers and third parties.  

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.